Cargando…

Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing

BACKGROUND: Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next‐generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic diso...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Sha, Wang, Li, Zhao, Dongying, Zhang, Yonghong, Chen, Yan, Tan, Jintong, Liang, Lili, Zhu, Tianwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565546/
https://www.ncbi.nlm.nih.gov/pubmed/30968598
http://dx.doi.org/10.1002/mgg3.684
_version_ 1783426666864836608
author Hong, Sha
Wang, Li
Zhao, Dongying
Zhang, Yonghong
Chen, Yan
Tan, Jintong
Liang, Lili
Zhu, Tianwen
author_facet Hong, Sha
Wang, Li
Zhao, Dongying
Zhang, Yonghong
Chen, Yan
Tan, Jintong
Liang, Lili
Zhu, Tianwen
author_sort Hong, Sha
collection PubMed
description BACKGROUND: Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next‐generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic disorders in a pediatric setting. METHODS: Next‐generation sequencing tests are performed for 98 unrelated Chinese patients within their first year of life, who were admitted to Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, during a 2‐year period. RESULTS: Clinical indications for NGS tests included a range of medical concerns. The mean age was 4.4 ± 4.2 months of age for infants undergoing targeting specific (known) disease‐causing genes (TRS) analysis, and 4.4 ± 4.3 months of age for whole‐exome sequencing (WES) (p > 0.05). A molecular diagnosis is done in 72 infants (73.47%), which finds a relatively high yield with phenotypes of metabolism/homeostasis abnormality (HP: 0001939) (odds ratio, 1.83; 95% CI, 0.56–6.04; p = 0.32) and a significantly low yield with atypical symptoms (without a definite HPO term) (odds ratio, 0.08; 95% CI, 0.01–0.73; p = 0.03). TRS analysis provides molecular yields higher than WES (p = 0.01). Ninety‐eight different mutations are discovered in 72 patients. Twenty‐seven of them have not been reported previously. Nearly half (43.06%, 31/72) of the patients are found to carry 11 common disorders, mostly being inborn errors of metabolism (IEM) and neurogenetic disorders and all of them are observed through TRS analysis. Eight positive cases are identified through WES, and all of them are sporadic, of highly variable phenotypes and severity. There are 26 patients with negative findings in this study. CONCLUSION: This study provides evidence that NGS can yield high success rates in a tertiary pediatric setting, but suggests that the scope of known Mendelian conditions may be considerably broader than currently recognized.
format Online
Article
Text
id pubmed-6565546
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65655462019-06-20 Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing Hong, Sha Wang, Li Zhao, Dongying Zhang, Yonghong Chen, Yan Tan, Jintong Liang, Lili Zhu, Tianwen Mol Genet Genomic Med Original Articles BACKGROUND: Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next‐generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic disorders in a pediatric setting. METHODS: Next‐generation sequencing tests are performed for 98 unrelated Chinese patients within their first year of life, who were admitted to Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, during a 2‐year period. RESULTS: Clinical indications for NGS tests included a range of medical concerns. The mean age was 4.4 ± 4.2 months of age for infants undergoing targeting specific (known) disease‐causing genes (TRS) analysis, and 4.4 ± 4.3 months of age for whole‐exome sequencing (WES) (p > 0.05). A molecular diagnosis is done in 72 infants (73.47%), which finds a relatively high yield with phenotypes of metabolism/homeostasis abnormality (HP: 0001939) (odds ratio, 1.83; 95% CI, 0.56–6.04; p = 0.32) and a significantly low yield with atypical symptoms (without a definite HPO term) (odds ratio, 0.08; 95% CI, 0.01–0.73; p = 0.03). TRS analysis provides molecular yields higher than WES (p = 0.01). Ninety‐eight different mutations are discovered in 72 patients. Twenty‐seven of them have not been reported previously. Nearly half (43.06%, 31/72) of the patients are found to carry 11 common disorders, mostly being inborn errors of metabolism (IEM) and neurogenetic disorders and all of them are observed through TRS analysis. Eight positive cases are identified through WES, and all of them are sporadic, of highly variable phenotypes and severity. There are 26 patients with negative findings in this study. CONCLUSION: This study provides evidence that NGS can yield high success rates in a tertiary pediatric setting, but suggests that the scope of known Mendelian conditions may be considerably broader than currently recognized. John Wiley and Sons Inc. 2019-04-09 /pmc/articles/PMC6565546/ /pubmed/30968598 http://dx.doi.org/10.1002/mgg3.684 Text en © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Hong, Sha
Wang, Li
Zhao, Dongying
Zhang, Yonghong
Chen, Yan
Tan, Jintong
Liang, Lili
Zhu, Tianwen
Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
title Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
title_full Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
title_fullStr Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
title_full_unstemmed Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
title_short Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
title_sort clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565546/
https://www.ncbi.nlm.nih.gov/pubmed/30968598
http://dx.doi.org/10.1002/mgg3.684
work_keys_str_mv AT hongsha clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT wangli clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT zhaodongying clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT zhangyonghong clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT chenyan clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT tanjintong clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT lianglili clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing
AT zhutianwen clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing